Introduction Relapsing multiple sclerosis (RMS) is characterized by episodes of acute demyelination and chronic neuroinflammation mediated by T cells, B cells, and microglia (1). Despite advances in disease-modifying therapies (DMTs), many patients continue to experience breakthrough disease activity or intolerance to lymphocyte-depleting treatment

In this engaging KOL (Key Opinion Leader) interview, we sit down with Dr. Dewansh Mishra, a leading DM Neuro-interventional Radiologist from Lucknow, Uttar Pradesh, to explore the complexities and evolving approaches in neurovascular care. Dr. Mishra demystifies the mechanisms, diagnosis, and modern interventional treatments for conditions such as

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.   FDA Approves Targeted Therapy for Relapsed CLL/SLL The U.S. Food and Drug Administration granted traditional approval for a targeted therapy for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphom

Introduction Central sleep apnea (CSA), majorly a post-hyperventilation phenomenon, is a form of sleep-disordered breathing (SDB) characterised by recurrent cessation or reduction of respiratory effort during sleep, leading to sleep fragmentation, decline in overall life quality, worsened clinical prognosis, and potential cardiovascular consequence

Introduction Tolebrutinib is a next-generation Bruton’s tyrosine kinase inhibitor designed to target inflammatory pathways that remain insufficiently controlled by current multiple sclerosis therapies (1). Through covalent BTK binding, it delivers durable and selective inhibition across peripheral immune cells and CNS-resident microglia (1). Its co

Introduction Multiple sclerosis (MS) remains driven by immune activity in both the periphery and the CNS, with microglial-mediated inflammation contributing significantly to disability progression (1). Bruton’s tyrosine kinase (BTK) is central to signaling in B cells and innate immune cells, making it an emerging target for comprehensive MS immune

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  New Gene Therapy Expands Treatment Options for SMA The FDA has approved a new intrathecal gene therapy for spinal muscular atrophy (SMA) in patients aged two years and older with confirmed SMN1 mutations. Delivered directly into the spina

The Wait Is Over – Discover the First BTKi for nrSPMS in the UAE: Cenrifki® Be part of an exclusive session unveiling a breakthrough in nrSPMS management —Cenrifki® (Tolebrutinib), advancing efficacy and safety in relapsing nrSPMS. Discover clinical insights and practical perspectives from leading experts. Watch the launch video now!